Ublituximab is a novel glycoengineered monoclonal antibody that targets a unique epitope on
CD20-expressing B-cells. When ublituximab binds to the B-cell it triggers a series of immunological
reactions (including antibody-dependent cellular cytotoxicity [ADCC] and complement dependent
cytotoxicity [CDC]), leading to destruction of the cell. Additionally, ublituximab is uniquely designed
to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a
process called glycoengineering, has been shown to enhance the potency of ublituximab, especially the
ADCC activity.
Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the
management of B-cell malignancies and autoimmune disorders, both diseases driven by the abnormal growth
or function of B-cells.
Please click here to view our Publications Page.
Azercabtagene zapreleucel (“azer-cel”) is an investigational anti-CD19 allogeneic chimeric antigen
receptor (CAR) T cell therapy. In contrast to autologous CAR T cell therapies which are made
individually from a patient’s own cells, azer-cel is an allogeneic or “off-the-shelf” therapy made from
donor-derived T cells, modified using a proprietary gene editing technology. Azer-cel recognizes
the well characterized B cell surface protein CD19 and is designed to avoid graft-versus-host disease, a
significant complication associated with other donor-derived, cell-based therapies.
Ublituximab is a novel glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. When ublituximab binds to the B-cell it triggers a series of immunological reactions (including antibody-dependent cellular cytotoxicity [ADCC] and complement dependent cytotoxicity [CDC]), leading to destruction of the cell. Additionally, ublituximab is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, has been shown to enhance the potency of ublituximab, especially the ADCC activity.
A subcutaneous (SUB-Q) formulation of ublituximab is currently being studied in a phase 3 clinical trial for adults with relapsing forms of multiple sclerosis (RMS).
Click here to learn more about the Phase 2 trial evaluating subcutaneous ublituximab.
CD20 IV
CD19 CAR-T
